Nuveen LLC Purchases Shares of 131,859 Arcus Biosciences, Inc. $RCUS

Nuveen LLC acquired a new stake in Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 131,859 shares of the company's stock, valued at approximately $1,035,000. Nuveen LLC owned approximately 0.12% of Arcus Biosciences at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Arcus Biosciences by 24.1% during the first quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company's stock worth $52,499,000 after purchasing an additional 1,298,584 shares during the period. Woodline Partners LP grew its holdings in Arcus Biosciences by 1.3% during the fourth quarter. Woodline Partners LP now owns 3,523,937 shares of the company's stock worth $52,471,000 after purchasing an additional 45,497 shares during the period. Dimensional Fund Advisors LP grew its holdings in Arcus Biosciences by 11.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,702,302 shares of the company's stock worth $25,348,000 after purchasing an additional 178,351 shares during the period. Ameriprise Financial Inc. grew its holdings in Arcus Biosciences by 17.3% during the fourth quarter. Ameriprise Financial Inc. now owns 1,547,591 shares of the company's stock worth $23,044,000 after purchasing an additional 228,325 shares during the period. Finally, Parkman Healthcare Partners LLC grew its holdings in Arcus Biosciences by 24.2% during the fourth quarter. Parkman Healthcare Partners LLC now owns 1,273,789 shares of the company's stock worth $18,967,000 after purchasing an additional 248,035 shares during the period. Institutional investors own 92.89% of the company's stock.

Arcus Biosciences Price Performance

Shares of NYSE RCUS traded down $0.07 during midday trading on Thursday, reaching $11.57. The company's stock had a trading volume of 1,151,157 shares, compared to its average volume of 1,007,394. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.50 and a current ratio of 4.50. Arcus Biosciences, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $18.98. The business's 50 day moving average price is $9.56 and its two-hundred day moving average price is $9.14. The company has a market cap of $1.23 billion, a P/E ratio of -3.65 and a beta of 0.83.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.11) earnings per share for the quarter, beating analysts' consensus estimates of ($1.14) by $0.03. Arcus Biosciences had a negative net margin of 109.56% and a negative return on equity of 55.96%. The company had revenue of $160.00 million during the quarter, compared to the consensus estimate of $32.86 million. During the same period in the previous year, the business earned ($1.02) earnings per share. The firm's quarterly revenue was up 310.3% on a year-over-year basis. On average, analysts forecast that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Wells Fargo & Company reduced their price objective on Arcus Biosciences from $26.00 to $25.00 and set an "overweight" rating for the company in a report on Thursday, August 7th. Wall Street Zen upgraded Arcus Biosciences from a "strong sell" rating to a "hold" rating in a report on Saturday, August 9th. Wedbush restated an "outperform" rating and set a $33.00 price objective on shares of Arcus Biosciences in a report on Wednesday, May 7th. Morgan Stanley reduced their price objective on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Finally, The Goldman Sachs Group reduced their price objective on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a report on Thursday, May 8th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $21.14.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.